<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;ff=20231028000931&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;ff=20231028000931&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Sat, 28 Oct 2023 04:09:33 +0000</lastbuilddate>
<pubDate>Fri, 27 Oct 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Inhibition of angiotensinogen in the treatment of hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37889202/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 27:ehad704. doi: 10.1093/eurheartj/ehad704. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37889202/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37889202</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad704>10.1093/eurheartj/ehad704</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37889202</guid>
<pubDate>Fri, 27 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:date>2023-10-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Inhibition of angiotensinogen in the treatment of hypertension</dc:title>
<dc:identifier>pmid:37889202</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad704</dc:identifier>
</item>
<item>
<title>The science and art of predicting recurrent VTE</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37889146/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 27:ehad712. doi: 10.1093/eurheartj/ehad712. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37889146/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37889146</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad712>10.1093/eurheartj/ehad712</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37889146</guid>
<pubDate>Fri, 27 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Marc Carrier</dc:creator>
<dc:creator>Peter Verhamme</dc:creator>
<dc:date>2023-10-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The science and art of predicting recurrent VTE</dc:title>
<dc:identifier>pmid:37889146</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad712</dc:identifier>
</item>
<item>
<title>Going green in cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37889072/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 27:ehad703. doi: 10.1093/eurheartj/ehad703. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37889072/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37889072</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad703>10.1093/eurheartj/ehad703</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37889072</guid>
<pubDate>Fri, 27 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Mohammed Y Khanji</dc:creator>
<dc:creator>Riyaz Patel</dc:creator>
<dc:creator>Fabrizio Ricci</dc:creator>
<dc:date>2023-10-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Going green in cardiology</dc:title>
<dc:identifier>pmid:37889072</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad703</dc:identifier>
</item>
<item>
<title>Icosapent ethyl for hypertriglyceridaemia and atherosclerosis: greater RESPECT for increased therapeutic use</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37889071/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 27:ehad668. doi: 10.1093/eurheartj/ehad668. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37889071/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37889071</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad668>10.1093/eurheartj/ehad668</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37889071</guid>
<pubDate>Fri, 27 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Prakriti Gaba</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>William E Boden</dc:creator>
<dc:date>2023-10-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Icosapent ethyl for hypertriglyceridaemia and atherosclerosis: greater RESPECT for increased therapeutic use</dc:title>
<dc:identifier>pmid:37889071</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad668</dc:identifier>
</item>
<item>
<title>Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37886885/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: For patients with catecholaminergic polymorphic ventricular tachycardia, adding flecainide to beta-blocker therapy was associated with a lower incidence of AEs in the overall cohort, in symptomatic patients, and particularly in patients with breakthrough AEs while on beta-blocker therapy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 27. doi: 10.1161/CIRCULATIONAHA.123.064786. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In severely affected patients with catecholaminergic polymorphic ventricular tachycardia, beta-blockers are often insufficiently protective. The purpose of this study was to evaluate whether flecainide is associated with a lower incidence of arrhythmic events (AEs) when added to beta-blockers in a large cohort of patients with catecholaminergic polymorphic ventricular tachycardia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: From 2 international registries, this multicenter case cross-over study included patients with a clinical or genetic diagnosis of catecholaminergic polymorphic ventricular tachycardia in whom flecainide was added to beta-blocker therapy. The study period was defined as the period in which background therapy (ie, beta-blocker type [beta1-selective or nonselective]), left cardiac sympathetic denervation, and implantable cardioverter defibrillator treatment status, remained unchanged within individual patients and was divided into pre-flecainide and on-flecainide periods. The primary end point was AEs, defined as sudden cardiac death, sudden cardiac arrest, appropriate implantable cardioverter defibrillator shock, and arrhythmic syncope. The association of flecainide with AE rates was assessed using a generalized linear mixed model assuming negative binomial distribution and random effects for patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 247 patients (123 [50%] females; median age at start of flecainide, 18 years [interquartile range, 14-29]; median flecainide dose, 2.2 mg/kg per day [interquartile range, 1.7-3.1]) were included. At baseline, all patients used a beta-blocker, 70 (28%) had an implantable cardioverter defibrillator, and 21 (9%) had a left cardiac sympathetic denervation. During a median pre-flecainide follow-up of 2.1 years (interquartile range, 0.4-7.2), 41 patients (17%) experienced 58 AEs (annual event rate, 5.6%). During a median on-flecainide follow-up of 2.9 years (interquartile range, 1.0-6.0), 23 patients (9%) experienced 38 AEs (annual event rate, 4.0%). There were significantly fewer AEs after initiation of flecainide (incidence rate ratio, 0.55 [95% CI, 0.38-0.83]; <i>P</i>=0.007). Among patients who were symptomatic before diagnosis or during the pre-flecainide period (n=167), flecainide was associated with significantly fewer AEs (incidence rate ratio, 0.49 [95% CI, 0.31-0.77]; <i>P</i>=0.002). Among patients with ≥1 AE on beta-blocker therapy (n=41), adding flecainide was also associated with significantly fewer AEs (incidence rate ratio, 0.25 [95% CI, 0.14-0.45]; <i>P</i>&lt;0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: For patients with catecholaminergic polymorphic ventricular tachycardia, adding flecainide to beta-blocker therapy was associated with a lower incidence of AEs in the overall cohort, in symptomatic patients, and particularly in patients with breakthrough AEs while on beta-blocker therapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37886885/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37886885</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064786>10.1161/CIRCULATIONAHA.123.064786</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37886885</guid>
<pubDate>Fri, 27 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Auke T Bergeman</dc:creator>
<dc:creator>Krystien V V Lieve</dc:creator>
<dc:creator>Dania Kallas</dc:creator>
<dc:creator>Johan M Bos</dc:creator>
<dc:creator>Ferran Roses Y Noguer</dc:creator>
<dc:creator>Isabelle Denjoy</dc:creator>
<dc:creator>Esther Zorio</dc:creator>
<dc:creator>Janneke A E Kammeraad</dc:creator>
<dc:creator>P J Peltenburg</dc:creator>
<dc:creator>Katie Tobert</dc:creator>
<dc:creator>Takeshi Aiba</dc:creator>
<dc:creator>Joseph Atallah</dc:creator>
<dc:creator>Fabrizio Drago</dc:creator>
<dc:creator>Anjan S Batra</dc:creator>
<dc:creator>Ramon Brugada</dc:creator>
<dc:creator>Martin Borggrefe</dc:creator>
<dc:creator>Sally-Ann B Clur</dc:creator>
<dc:creator>Moniek G P J Cox</dc:creator>
<dc:creator>Andrew Davis</dc:creator>
<dc:creator>Santokh Dhillon</dc:creator>
<dc:creator>Susan P Etheridge</dc:creator>
<dc:creator>Peter Fischbach</dc:creator>
<dc:creator>Sonia Franciosi</dc:creator>
<dc:creator>Kristina Haugaa</dc:creator>
<dc:creator>Minoru Horie</dc:creator>
<dc:creator>Christopher Johnsrude</dc:creator>
<dc:creator>Austin M Kane</dc:creator>
<dc:creator>Ulrich Krause</dc:creator>
<dc:creator>Sit-Yee Kwok</dc:creator>
<dc:creator>Martin J LaPage</dc:creator>
<dc:creator>Seiko Ohno</dc:creator>
<dc:creator>Vincent Probst</dc:creator>
<dc:creator>Jason D Roberts</dc:creator>
<dc:creator>Tomas Robyns</dc:creator>
<dc:creator>Frederic Sacher</dc:creator>
<dc:creator>Christopher Semsarian</dc:creator>
<dc:creator>Jonathan R Skinner</dc:creator>
<dc:creator>Heikki Swan</dc:creator>
<dc:creator>Terezia Tavacova</dc:creator>
<dc:creator>Svjetlana Tisma-Dupanovic</dc:creator>
<dc:creator>Jacob Tfelt-Hansen</dc:creator>
<dc:creator>Sing-Chien Yap</dc:creator>
<dc:creator>Prince J Kannankeril</dc:creator>
<dc:creator>Antoine Leenhardt</dc:creator>
<dc:creator>Janice Till</dc:creator>
<dc:creator>Shubhayan Sanatani</dc:creator>
<dc:creator>Michael W T Tanck</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>Arthur A M Wilde</dc:creator>
<dc:creator>Christian van der Werf</dc:creator>
<dc:date>2023-10-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia</dc:title>
<dc:identifier>pmid:37886885</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064786</dc:identifier>
</item>
<item>
<title>MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37886847/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Our results show that sarcomere mutations induce cardiomyocyte MDM2 signaling during the earliest stages of disease, and this leads to long-term changes in the myocardial microenvironment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 27. doi: 10.1161/CIRCULATIONAHA.123.064332. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Microvasculature dysfunction is a common finding in pathologic remodeling of the heart and is thought to play an important role in the pathogenesis of hypertrophic cardiomyopathy (HCM), a disease caused by sarcomere gene mutations. We hypothesized that microvascular dysfunction in HCM was secondary to abnormal microvascular growth and could occur independent of ventricular hypertrophy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used multimodality imaging methods to track the temporality of microvascular dysfunction in HCM mouse models harboring mutations in the sarcomere genes <i>Mybpc3</i>(cardiac myosin binding protein 3) or <i>Myh6</i> (myosin heavy chain 6). We performed complementary molecular methods to assess protein quantity, interactions, and post-translational modifications to identify mechanisms regulating this response. We manipulated select molecular pathways in vivo using both genetic and pharmacological methods to validate these mechanisms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found that microvascular dysfunction in our HCM models occurred secondary to reduced myocardial capillary growth during the early postnatal time period and could occur before the onset of myocardial hypertrophy. We discovered that the E3 ubiquitin protein ligase MDM2 (murine double minute 2) dynamically regulates the protein stability of both HIF1α (hypoxia-inducible factor 1 alpha) and HIF2α (hypoxia-inducible factor 2 alpha)/EPAS1 (endothelial PAS domain protein 1) through canonical and noncanonical mechanisms. The resulting HIF imbalance leads to reduced proangiogenic gene expression during a key period of myocardial capillary growth. Reducing MDM2 protein levels by genetic or pharmacological methods normalized HIF protein levels and prevented the development of microvascular dysfunction in both HCM models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our results show that sarcomere mutations induce cardiomyocyte MDM2 signaling during the earliest stages of disease, and this leads to long-term changes in the myocardial microenvironment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37886847/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37886847</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064332>10.1161/CIRCULATIONAHA.123.064332</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37886847</guid>
<pubDate>Fri, 27 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Puneeth Shridhar</dc:creator>
<dc:creator>Michael S Glennon</dc:creator>
<dc:creator>Soumojit Pal</dc:creator>
<dc:creator>Christina J Waldron</dc:creator>
<dc:creator>Ethan J Chetkof</dc:creator>
<dc:creator>Payel Basak</dc:creator>
<dc:creator>Nicolas G Clavere</dc:creator>
<dc:creator>Dipanjan Banerjee</dc:creator>
<dc:creator>Sebastien Gingras</dc:creator>
<dc:creator>Jason R Becker</dc:creator>
<dc:date>2023-10-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:37886847</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064332</dc:identifier>
</item>
<item>
<title>Versican Promotes Cardiomyocyte Proliferation and Cardiac Repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37886839/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Our study identifies versican as a cardiac fibroblast-derived pro-proliferative proteoglycan and clarifies the role of versican in promoting adult cardiac repair. These findings highlight its potential as a therapeutic factor for ischemic heart diseases.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 27. doi: 10.1161/CIRCULATIONAHA.123.066298. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The adult mammalian heart is incapable of regeneration, whereas a transient regenerative capacity is maintained in the neonatal heart, primarily through the proliferation of preexisting cardiomyocytes. Neonatal heart regeneration after myocardial injury is accompanied by an expansion of cardiac fibroblasts and compositional changes in the extracellular matrix. Whether and how these changes influence cardiomyocyte proliferation and heart regeneration remains to be investigated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used apical resection and myocardial infarction surgical models in neonatal and adult mice to investigate extracellular matrix components involved in heart regeneration after injury. Single-cell RNA sequencing and liquid chromatography-mass spectrometry analyses were used for versican identification. Cardiac fibroblast-specific <i>Vcan</i> deletion was achieved using the mouse strains <i>Col1a2-2A-CreER</i> and <i>Vcan</i><sup><i>fl/fl</i></sup>. Molecular signaling pathways related to the effects of versican were assessed through Western blot, immunostaining, and quantitative reverse transcription polymerase chain reaction. Cardiac fibrosis and heart function were evaluated by Masson trichrome staining and echocardiography, respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Versican, a cardiac fibroblast-derived extracellular matrix component, was upregulated after neonatal myocardial injury and promoted cardiomyocyte proliferation. Conditional knockout of <i>Vcan</i> in cardiac fibroblasts decreased cardiomyocyte proliferation and impaired neonatal heart regeneration. In adult mice, intramyocardial injection of versican after myocardial infarction enhanced cardiomyocyte proliferation, reduced fibrosis, and improved cardiac function. Furthermore, versican augmented the proliferation of human induced pluripotent stem cell-derived cardiomyocytes. Mechanistically, versican activated integrin β1 and downstream signaling molecules, including ERK1/2 and Akt, thereby promoting cardiomyocyte proliferation and cardiac repair.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study identifies versican as a cardiac fibroblast-derived pro-proliferative proteoglycan and clarifies the role of versican in promoting adult cardiac repair. These findings highlight its potential as a therapeutic factor for ischemic heart diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37886839/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37886839</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066298>10.1161/CIRCULATIONAHA.123.066298</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37886839</guid>
<pubDate>Fri, 27 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Jie Feng</dc:creator>
<dc:creator>Yandong Li</dc:creator>
<dc:creator>Yan Li</dc:creator>
<dc:creator>Qianqian Yin</dc:creator>
<dc:creator>Haotong Li</dc:creator>
<dc:creator>Jun Li</dc:creator>
<dc:creator>Bin Zhou</dc:creator>
<dc:creator>Jian Meng</dc:creator>
<dc:creator>Hong Lian</dc:creator>
<dc:creator>Mengge Wu</dc:creator>
<dc:creator>Yahuan Li</dc:creator>
<dc:creator>Kefei Dou</dc:creator>
<dc:creator>Weihua Song</dc:creator>
<dc:creator>Bin Lu</dc:creator>
<dc:creator>Lihui Liu</dc:creator>
<dc:creator>Shengshou Hu</dc:creator>
<dc:creator>Yu Nie</dc:creator>
<dc:date>2023-10-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Versican Promotes Cardiomyocyte Proliferation and Cardiac Repair</dc:title>
<dc:identifier>pmid:37886839</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066298</dc:identifier>
</item>
<item>
<title>The microvascular resistance reserve: one size fits all, but mostly one</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37885331/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 27:ehad698. doi: 10.1093/eurheartj/ehad698. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37885331/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37885331</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad698>10.1093/eurheartj/ehad698</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37885331</guid>
<pubDate>Fri, 27 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Coen K M Boerhout</dc:creator>
<dc:creator>Jan J Piek</dc:creator>
<dc:creator>Tim P van de Hoef</dc:creator>
<dc:date>2023-10-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The microvascular resistance reserve: one size fits all, but mostly one</dc:title>
<dc:identifier>pmid:37885331</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad698</dc:identifier>
</item>
<item>
<title>Microvascular resistance reserve, does one size fit all?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37885322/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 27:ehad691. doi: 10.1093/eurheartj/ehad691. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37885322/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37885322</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad691>10.1093/eurheartj/ehad691</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37885322</guid>
<pubDate>Fri, 27 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Tijn P J Jansen</dc:creator>
<dc:creator>Caïa Crooijmans</dc:creator>
<dc:creator>Peter Damman</dc:creator>
<dc:date>2023-10-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Microvascular resistance reserve, does one size fit all?</dc:title>
<dc:identifier>pmid:37885322</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad691</dc:identifier>
</item>
<item>
<title>Ventricular septal defect combined with double-chambered right ventricle and severe right ventricular outflow tract stenosis in a symptom-free septuagenarian</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37885264/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 27:ehad697. doi: 10.1093/eurheartj/ehad697. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37885264/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37885264</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad697>10.1093/eurheartj/ehad697</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37885264</guid>
<pubDate>Fri, 27 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Jieun Lee</dc:creator>
<dc:creator>Man-Jong Baek</dc:creator>
<dc:creator>Jah Yeon Choi</dc:creator>
<dc:date>2023-10-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Ventricular septal defect combined with double-chambered right ventricle and severe right ventricular outflow tract stenosis in a symptom-free septuagenarian</dc:title>
<dc:identifier>pmid:37885264</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad697</dc:identifier>
</item>
<item>
<title>Nutrient-regulated control of lysosome function by signaling lipid conversion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37883971/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>Lysosomes serve dual antagonistic functions in cells by mediating anabolic growth signaling and the catabolic turnover of macromolecules. How these janus-faced activities are regulated in response to cellular nutrient status is poorly understood. We show here that lysosome morphology and function are reversibly controlled by a nutrient-regulated signaling lipid switch that triggers the conversion between peripheral motile mTOR complex 1 (mTORC1) signaling-active and static mTORC1-inactive...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Oct 18:S0092-8674(23)01081-4. doi: 10.1016/j.cell.2023.09.027. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Lysosomes serve dual antagonistic functions in cells by mediating anabolic growth signaling and the catabolic turnover of macromolecules. How these janus-faced activities are regulated in response to cellular nutrient status is poorly understood. We show here that lysosome morphology and function are reversibly controlled by a nutrient-regulated signaling lipid switch that triggers the conversion between peripheral motile mTOR complex 1 (mTORC1) signaling-active and static mTORC1-inactive degradative lysosomes clustered at the cell center. Starvation-triggered relocalization of phosphatidylinositol 4-phosphate (PI(4)P)-metabolizing enzymes reshapes the lysosomal surface proteome to facilitate lysosomal proteolysis and to repress mTORC1 signaling. Concomitantly, lysosomal phosphatidylinositol 3-phosphate (PI(3)P), which marks motile signaling-active lysosomes in the cell periphery, is erased. Interference with this PI(3)P/PI(4)P lipid switch module impairs the adaptive response of cells to altering nutrient supply. Our data unravel a key function for lysosomal phosphoinositide metabolism in rewiring organellar membrane dynamics in response to cellular nutrient status.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37883971/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37883971</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.09.027>10.1016/j.cell.2023.09.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37883971</guid>
<pubDate>Thu, 26 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Michael Ebner</dc:creator>
<dc:creator>Dmytro Puchkov</dc:creator>
<dc:creator>Orestes López-Ortega</dc:creator>
<dc:creator>Pathma Muthukottiappan</dc:creator>
<dc:creator>Yanwei Su</dc:creator>
<dc:creator>Christopher Schmied</dc:creator>
<dc:creator>Silke Zillmann</dc:creator>
<dc:creator>Iryna Nikonenko</dc:creator>
<dc:creator>Jochen Koddebusch</dc:creator>
<dc:creator>Gillian L Dornan</dc:creator>
<dc:creator>Max T Lucht</dc:creator>
<dc:creator>Vonda Koka</dc:creator>
<dc:creator>Wonyul Jang</dc:creator>
<dc:creator>Philipp Alexander Koch</dc:creator>
<dc:creator>Alexander Wallroth</dc:creator>
<dc:creator>Martin Lehmann</dc:creator>
<dc:creator>Britta Brügger</dc:creator>
<dc:creator>Mario Pende</dc:creator>
<dc:creator>Dominic Winter</dc:creator>
<dc:creator>Volker Haucke</dc:creator>
<dc:date>2023-10-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Nutrient-regulated control of lysosome function by signaling lipid conversion</dc:title>
<dc:identifier>pmid:37883971</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.09.027</dc:identifier>
</item>
<item>
<title>Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure at 6 Months Following Medication Escalation: The RADIANCE Clinical Trial Program</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37883784/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>Background: The RADIANCE-HTN SOLO, RADIANCE-HTN TRIO, and RADIANCE II randomized, sham-controlled trials independently met their primary endpoint of a greater reduction in daytime ambulatory systolic blood pressure (SBP) at 2 months after ultrasound renal denervation (uRDN) in patients with hypertension. To characterize the longer-term effectiveness and safety of uRDN vs. sham at 6 months, following the blinded addition of antihypertensive treatments (AHT), we pooled individual patient data...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 26. doi: 10.1161/CIRCULATIONAHA.123.066941. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> The RADIANCE-HTN SOLO, RADIANCE-HTN TRIO, and RADIANCE II randomized, sham-controlled trials independently met their primary endpoint of a greater reduction in daytime ambulatory systolic blood pressure (SBP) at 2 months after ultrasound renal denervation (uRDN) in patients with hypertension. To characterize the longer-term effectiveness and safety of uRDN vs. sham at 6 months, following the blinded addition of antihypertensive treatments (AHT), we pooled individual patient data across these three similarly designed trials. <b>Methods:</b> Patients with mild-to-moderate hypertension on no AHT or with hypertension resistant to standardized combination triple AHT were randomized to uRDN (n=293 in total) vs. sham (n=213 in total); they were to remain off added AHT throughout 2 months of follow-up unless specified BP criteria were exceeded. In each trial, if monthly home BP was ≥135/85 mmHg from 2 to 5 months, standardized AHT was sequentially added to target home BP &lt;135/85 mmHg under blinding to initial treatment assignment. Six-month outcomes included (1) baseline- and AHT-adjusted change in daytime ambulatory, home, and office SBP, (2) change in AHT, and (3) safety. Linear mixed regression models using all BP measurements and change in AHT from baseline through 6 months were used. <b>Results:</b> Patients (70% men) were aged 54.1±9.3 years with baseline daytime ambulatory/home/office SBP of 150.5±9.8/151.0±12.4/155.5±14.4 mmHg, respectively. From 2 to 6 months, BP decreased in both groups with AHT titration but fewer uRDN patients were prescribed AHT (P=0.004), and fewer additional AHT were prescribed to uRDN patients vs. sham patients (P=0.001). While unadjusted between-group difference in daytime ambulatory SBP was similar at 6 months, the baseline and medication-adjusted between-group difference at 6 months was -3.0 mmHg (95%CI: -5.7,-0.2; p=0.033) in favor of uRDN+AHT. For home and office SBP, the adjusted between-group differences in favor of uRDN+AHT over 6 months were -5.4 mmHg (-6.8, -4.0; P&lt;0.001) and -5.2 mmHg (-7.1,-3.3; P&lt;0.001), respectively. There was no heterogeneity between trials. Safety outcomes were few and did not differ between groups. <b>Conclusions:</b> This individual patient-data analysis of 506 patients included in RADIANCE trials demonstrates the maintenance of BP-lowering efficacy of uRDN vs. sham at 6 months, with fewer added AHT.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37883784/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37883784</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066941>10.1161/CIRCULATIONAHA.123.066941</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37883784</guid>
<pubDate>Thu, 26 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Michel Azizi</dc:creator>
<dc:creator>Andrew S P Sharp</dc:creator>
<dc:creator>Naomi D L Fisher</dc:creator>
<dc:creator>Michael A Weber</dc:creator>
<dc:creator>Melvin D Lobo</dc:creator>
<dc:creator>Joost Daemen</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Felix Mahfoud</dc:creator>
<dc:creator>Roland E Schmieder</dc:creator>
<dc:creator>Jan Basile</dc:creator>
<dc:creator>Michael J Bloch</dc:creator>
<dc:creator>Manish Saxena</dc:creator>
<dc:creator>Yale Wang</dc:creator>
<dc:creator>Kintur Sanghvi</dc:creator>
<dc:creator>J Stephen Jenkins</dc:creator>
<dc:creator>Chandan Devireddy</dc:creator>
<dc:creator>Florian Rader</dc:creator>
<dc:creator>Philippe Gosse</dc:creator>
<dc:creator>Lisa Claude</dc:creator>
<dc:creator>Dimitri A Augustin</dc:creator>
<dc:creator>Candace K McClure</dc:creator>
<dc:creator>Ajay J Kirtane</dc:creator>
<dc:creator>RADIANCE Investigators</dc:creator>
<dc:date>2023-10-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure at 6 Months Following Medication Escalation: The RADIANCE Clinical Trial Program</dc:title>
<dc:identifier>pmid:37883784</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066941</dc:identifier>
</item>
<item>
<title>Be aware and hit hard and early: oesophageal lesions after atrial fibrillation ablation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37883705/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 26:ehad692. doi: 10.1093/eurheartj/ehad692. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37883705/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37883705</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad692>10.1093/eurheartj/ehad692</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37883705</guid>
<pubDate>Thu, 26 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Roland Richard Tilz</dc:creator>
<dc:creator>Christian-H Heeger</dc:creator>
<dc:date>2023-10-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Be aware and hit hard and early: oesophageal lesions after atrial fibrillation ablation</dc:title>
<dc:identifier>pmid:37883705</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad692</dc:identifier>
</item>
<item>
<title>Left atrial pressure-assisted acute heart failure management in the cardiac intensive care unit: a proof-of-concept</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37883701/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 26:ehad730. doi: 10.1093/eurheartj/ehad730. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37883701/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37883701</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad730>10.1093/eurheartj/ehad730</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37883701</guid>
<pubDate>Thu, 26 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Attilio Restivo</dc:creator>
<dc:creator>Donato Antonio Paglianiti</dc:creator>
<dc:creator>Domenico D'Amario</dc:creator>
<dc:date>2023-10-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Left atrial pressure-assisted acute heart failure management in the cardiac intensive care unit: a proof-of-concept</dc:title>
<dc:identifier>pmid:37883701</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad730</dc:identifier>
</item>
<item>
<title>Early identification of oesophageal lesions after atrial fibrillation ablation to prevent atrio-oesophageal fistula</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37883700/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 26:ehad689. doi: 10.1093/eurheartj/ehad689. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37883700/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37883700</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad689>10.1093/eurheartj/ehad689</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37883700</guid>
<pubDate>Thu, 26 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Mauricio Scanavacca</dc:creator>
<dc:creator>Cristiano Pisani</dc:creator>
<dc:creator>Esteban W R Rivarola</dc:creator>
<dc:date>2023-10-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Early identification of oesophageal lesions after atrial fibrillation ablation to prevent atrio-oesophageal fistula</dc:title>
<dc:identifier>pmid:37883700</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad689</dc:identifier>
</item>
<item>
<title>Transcatheter or Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Small Aortic Annulus: A Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37883682/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>Background: The optimal treatment in patients with severe aortic stenosis (AS) and small aortic annulus (SAA) remains to be determined. The objectives of this study were to compare the hemodynamic and clinical outcomes between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with a SAA. Methods: Prospective multicenter international randomized trial performed in 15 university hospitals. Participants were 151 patients with severe AS and SAA...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 26. doi: 10.1161/CIRCULATIONAHA.123.067326. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> The optimal treatment in patients with severe aortic stenosis (AS) and small aortic annulus (SAA) remains to be determined. The objectives of this study were to compare the hemodynamic and clinical outcomes between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with a SAA. <b>Methods:</b> Prospective multicenter international randomized trial performed in 15 university hospitals. Participants were 151 patients with severe AS and SAA (mean diameter &lt;23 mm) were randomized (1:1) to TAVR (n=77) vs SAVR (n=74), The primary outcome was impaired valve hemodynamics (i.e. severe prosthesis patient mismatch [PPM ] or moderate-severe aortic regurgitation [AR]) at 60 days as evaluated by Doppler-echocardiography and analyzed in a central echocardiography core laboratory. Clinical events were secondary outcomes. <b>Results:</b> The mean age of the participants was 75±5 years, with 140 (93%) women, a median STS of 2.50 (1.67-3.28)%, and a median annulus diameter of 21.1 (IQR: 20.4-22.0) mm. There were no differences between groups in the rate of severe PPM or moderate-severe AR (severe PPM (TAVR: 4 [5.6 %], SAVR: 7 [10.3%], p=0.30), and moderate-severe AR (none in both groups). There were no differences between groups regarding mortality (TAVR: 1 [1.3%], SAVR: 1 [1.4%], p=1.00) and stroke (TAVR:0, SAVR: 2 [2.7%], p=0.24) at 30 days. After a median follow-up of 2 (1-4) years, there were no differences between groups regarding mortality (TAVR: 7 [9.1%], SAVR: 6 [8.1%], p=0.89), stroke (TAVR: 3 [3.9%], SAVR: 3 [4.1%], p=0.95), and cardiac hospitalization (TAVR: 15 [19.5%], SAVR: 15 [ 20.3%], p=0.80). <b>Conclusions:</b> In patients with severe AS and SAA (women in the vast majority), there was no evidence of superiority of contemporary TAVR vs. SAVR regarding valve hemodynamic results. After a median follow-up of 2 years, there were no differences in clinical outcomes between groups. These findings suggest that the 2 therapies represent a valid alternative for treating patients with SA and SAA, and treatment selection should likely be individualized according to baseline characteristics, additional anatomical risk factors, and patient preference. However, the results of this study should be interpreted with caution due to the limited sample size leading to an underpowered study, and need to be confirmed in future larger studies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37883682/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37883682</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067326>10.1161/CIRCULATIONAHA.123.067326</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37883682</guid>
<pubDate>Thu, 26 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Josep Rodés-Cabau</dc:creator>
<dc:creator>Henrique Ribeiro</dc:creator>
<dc:creator>Siamak Mohammadi</dc:creator>
<dc:creator>Vicenç Serra</dc:creator>
<dc:creator>Talal Al-Atassi</dc:creator>
<dc:creator>Andres Iniguez</dc:creator>
<dc:creator>Victoria Vilalta</dc:creator>
<dc:creator>Luis Nombela-Franco</dc:creator>
<dc:creator>Jose Ignacio Saez de Ibarra</dc:creator>
<dc:creator>Vincent Auffret</dc:creator>
<dc:creator>Jessica Forcillo</dc:creator>
<dc:creator>Lenard Conradi</dc:creator>
<dc:creator>Marina Urena</dc:creator>
<dc:creator>Cesar Moris</dc:creator>
<dc:creator>Antonio Muñoz-Garcia</dc:creator>
<dc:creator>Jean-Michel Paradis</dc:creator>
<dc:creator>Eric Dumont</dc:creator>
<dc:creator>Dimitri Kalavrouziotis</dc:creator>
<dc:creator>Pablo Maria Pomerantzeff</dc:creator>
<dc:creator>Vitor Emer Egypto Rosa</dc:creator>
<dc:creator>Mariana Pezzute Lopes</dc:creator>
<dc:creator>Carlos Sureda</dc:creator>
<dc:creator>Victor Alfonso Jimenez Diaz</dc:creator>
<dc:creator>Carlos Giuliani</dc:creator>
<dc:creator>Marisa Avvedimento</dc:creator>
<dc:creator>Emilie Pelletier-Beaumont</dc:creator>
<dc:creator>Philippe Pibarot</dc:creator>
<dc:creator>VIVA Trial Investigators</dc:creator>
<dc:date>2023-10-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Transcatheter or Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Small Aortic Annulus: A Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37883682</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067326</dc:identifier>
</item>
<item>
<title>Ins and Outs of Glutathione in Cardiac Ischemia/Reperfusion Injury</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37883592/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Oct 27;133(10):877-879. doi: 10.1161/CIRCRESAHA.123.323715. Epub 2023 Oct 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37883592/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37883592</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323715>10.1161/CIRCRESAHA.123.323715</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37883592</guid>
<pubDate>Thu, 26 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Edoardo Bertero</dc:creator>
<dc:creator>Christoph Maack</dc:creator>
<dc:date>2023-10-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Ins and Outs of Glutathione in Cardiac Ischemia/Reperfusion Injury</dc:title>
<dc:identifier>pmid:37883592</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323715</dc:identifier>
</item>
<item>
<title>Transcriptional Control of Endothelial Senescence and Vascular Repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37883591/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Oct 27;133(10):858-860. doi: 10.1161/CIRCRESAHA.123.323716. Epub 2023 Oct 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37883591/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37883591</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323716>10.1161/CIRCRESAHA.123.323716</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37883591</guid>
<pubDate>Thu, 26 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Assam El-Osta</dc:creator>
<dc:date>2023-10-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Transcriptional Control of Endothelial Senescence and Vascular Repair</dc:title>
<dc:identifier>pmid:37883591</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323716</dc:identifier>
</item>
<item>
<title>Correction to: CTLA-4 Pathway Is Instrumental in Giant Cell Arteritis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37883590/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Oct 27;133(10):e51. doi: 10.1161/RES.0000000000000637. Epub 2023 Oct 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37883590/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37883590</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000637>10.1161/RES.0000000000000637</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37883590</guid>
<pubDate>Thu, 26 Oct 2023 06:00:00 -0400</pubDate>
<dc:date>2023-10-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Correction to: CTLA-4 Pathway Is Instrumental in Giant Cell Arteritis</dc:title>
<dc:identifier>pmid:37883590</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000637</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37883589/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Oct 27;133(10):790. doi: 10.1161/RES.0000000000000641. Epub 2023 Oct 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37883589/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37883589</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000641>10.1161/RES.0000000000000641</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37883589</guid>
<pubDate>Thu, 26 Oct 2023 06:00:00 -0400</pubDate>
<dc:date>2023-10-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:37883589</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000641</dc:identifier>
</item>
<item>
<title>In This Issue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37883588/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231028000931&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Oct 27;133(10):789. doi: 10.1161/RES.0000000000000640. Epub 2023 Oct 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37883588/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231028000931&v=2.17.9.post6+86293ac">37883588</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000640>10.1161/RES.0000000000000640</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37883588</guid>
<pubDate>Thu, 26 Oct 2023 06:00:00 -0400</pubDate>
<dc:date>2023-10-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>In This Issue</dc:title>
<dc:identifier>pmid:37883588</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000640</dc:identifier>
</item>





























</channel>
</rss>